Trial Profile
A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Conjugated estrogens/bazedoxifene (Primary) ; Bazedoxifene; Conjugated estrogens/medroxyprogesterone
- Indications Menopausal syndrome; Postmenopausal osteoporosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SMART-5
- Sponsors Pfizer; Wyeth
- 08 Oct 2016 Pooled post hoc analysis results of SMART-1 (NCT00675688), SMART-2 (NCT00234819), SMART-3 (NCT00238732), SMART-4 (NCT00242710), and SMART-5 (NCT00808132) presented at the 27th North American Menopause Society
- 09 Feb 2015 According to a Ligand Pharmaceuticals media release, Pfizer received EU marketing approval for DUAVIVE based on the data from this study.
- 12 Oct 2013 Pooled tolerability results presented at the 24th Annual Meeting of the North American Menopause Society.